Trastuzumab cardiotoxicity: from clinical trials to experimental studies

Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study

(2016) Inna Y. Gong et al.   BREAST CANCER RESEARCH AND TREATMENT

Drug-induced mitochondrial dysfunction and cardiotoxicity

(2015) Zoltán V Varga et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Cardiotoxicity Related to Long-Term Trastuzumab Therapy in Metastatic Breast Cancer: The Potential Role of Treatment Duration and Cardiac Risk Factors

(2015) Barbara Pistilli et al.   Breast Journal

The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors

(2015) Stephen PH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

(2015) Stephen PH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents

(2015) Denise A. Yardley et al.   CANCER JOURNAL

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

(2015) Sara M. Tolaney et al.   NEW ENGLAND JOURNAL OF MEDICINE

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

(2015) Christopher Southan et al.   NUCLEIC ACIDS RESEARCH

Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms

(2015) Luc Rochette et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

(2014) J. Baselga et al.   ANNALS OF ONCOLOGY

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

(2014) Evandro de Azambuja et al.   JOURNAL OF CLINICAL ONCOLOGY

Doxorubicin and Trastuzumab Regimen Induces Biventricular Failure in Mice

(2014) Giuseppina Milano et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

(2014) Ian E Krop et al.   LANCET ONCOLOGY

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

(2013) A. Schneeweiss et al.   ANNALS OF ONCOLOGY

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer

(2013) Alvaro Moreno-Aspitia et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2013) Sara A. Hurvitz et al.   JOURNAL OF CLINICAL ONCOLOGY

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

(2013) Aron Goldhirsch et al.   LANCET

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

(2013) André Robidoux et al.   LANCET ONCOLOGY

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity

(2013) Brian C Jensen et al.   PHARMACOGENOMICS

Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice

(2013) M. Khair ElZarrad et al.   PLoS One

Neuregulin in Cardiovascular Development and Disease

(2012) Oghenerukevwe Odiete et al.   CIRCULATION RESEARCH

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)

(2012) Kenjiro Aogi et al.   International Journal of Clinical Oncology

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

(2012) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

(2012) Valentina Guarneri et al.   JOURNAL OF CLINICAL ONCOLOGY

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2012) Edward H. Romond et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial

(2011) D. Rayson et al.   ANNALS OF ONCOLOGY

Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study

(2011) M. Martin et al.   ANNALS OF ONCOLOGY

p95HER2 and Breast Cancer

(2011) J. Arribas et al.   CANCER RESEARCH

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer

(2011) D. Amadori et al.   EUROPEAN JOURNAL OF CANCER

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

(2011) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study

(2010) A. Anton et al.   ANNALS OF ONCOLOGY

A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer

(2010) M. Venturini et al.   BREAST

Nox2 NADPH Oxidase Promotes Pathologic Cardiac Remodeling Associated with Doxorubicin Chemotherapy

(2010) Y. Zhao et al.   CANCER RESEARCH

Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

(2010) M. Scaltriti et al.   CLINICAL CANCER RESEARCH

First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) Trial

(2010) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neu–Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea

(2010) Chau Dang et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients WithHER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

(2010) Vicente Valero et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

(2010) Luca Gianni et al.   LANCET

Doxorubicin In Vivo Rapidly Alters Expression and Translation of Myocardial Electron Transport Chain Genes, Leads to ATP Loss and Caspase 3 Activation

(2010) Amy V. Pointon et al.   PLoS One

Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro

(2009) Partha Mukhopadhyay et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

(2009) Marc Spielmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

(2009) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel inHER2-Positive Metastatic Breast Cancer

(2009) Andrew M. Wardley et al.   JOURNAL OF CLINICAL ONCOLOGY

A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis

(2009) K. Pedersen et al.   MOLECULAR AND CELLULAR BIOLOGY

Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer

(2009) Christos Christodoulou et al.   ONCOLOGY

Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer

(2008) Alessandra Gennari et al.   BREAST CANCER RESEARCH AND TREATMENT

Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

(2008) C. C. Portera et al.   CLINICAL CANCER RESEARCH

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study

(2008) J. Cortes et al.   CLINICAL CANCER RESEARCH

The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer

(2008) Chau Dang et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

(2008) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY